drugset / Trial / NCT01424124
Safety and Efficacy of YHD001 in Asthma
RandomizedParallel-groupTriple-blindTreatment
Summary
The main objective is to evaluate the safety/tolerability and efficacy of YHD001 compared to singulair or placebo in patients (n=96) with partially controlled asthma. The study will conduct with 4 comparative groups orally treated with YHD001 dose level 1(t.i.d.), YHD001 dose level 2(t.i.d.), singulair 10mg(q.d.) or Placebo for 8 weeks.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-06
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Montelukast | Other / unclassified | 10 mg | Oral |
| Subject | YHD001 | Unknown | — | Oral |